Home › Compare › CEOS vs JNJ

CEOS vs JNJ: Dividend Comparison 2026

CEOS yields 76923.08% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CEOS wins by $3.5207463509675137e+25M in total portfolio value
10 years
CEOS
CEOS
● Live price
76923.08%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.5207463509675137e+25M
Annual income
$35,117,657,238,443,270,000,000,000,000,000.00
Full CEOS calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — CEOS vs JNJ

📍 CEOS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCEOSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CEOS + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CEOS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CEOS
Annual income on $10K today (after 15% tax)
$6,538,461.54/yr
After 10yr DRIP, annual income (after tax)
$29,850,008,652,676,780,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, CEOS beats the other by $29,850,008,652,676,780,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CEOS + JNJ for your $10,000?

CEOS: 50%JNJ: 50%
100% JNJ50/50100% CEOS
Portfolio after 10yr
$1.7603731754837569e+25M
Annual income
$17,558,828,619,221,635,000,000,000,000,000.00/yr
Blended yield
99.74%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CEOS
No analyst data
Altman Z
-2.9
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CEOS buys
0
JNJ buys
0
No recent congressional trades found for CEOS or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCEOSJNJ
Forward yield76923.08% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$3.5207463509675137e+25M$20.0K ✓
Annual income after 10y$35,117,657,238,443,270,000,000,000,000,000.00 ✓$827.78
Total dividends collected$3.520157521397876e+25M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CEOS vs JNJ ($10,000, DRIP)

YearCEOS PortfolioCEOS Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$7,703,008$7,692,307.69$10,676$355.77+$7.69M → CEOS
2$5,545,990,379$5,537,748,161.26$11,407$389.39+$5545.98M → CEOS
3$3,732,151,735,917$3,726,217,526,211.36$12,198$426.53+$3732151.72M → CEOS
4$2,347,491,508,714,269$2,343,498,106,356,837.00$13,056$467.62+$2347491508.70M → CEOS
5$1,380,119,533,083,814,100$1,377,607,717,169,489,700.00$13,987$513.12+$1380119533083.80M → CEOS
6$758,404,537,995,947,800,000$756,927,810,095,548,100,000.00$14,998$563.56+$758404537995947.75M → CEOS
7$389,547,620,856,236,000,000,000$388,736,128,000,580,400,000,000.00$16,098$619.52+$389547620856236032.00M → CEOS
8$187,025,031,600,452,680,000,000,000$186,608,215,646,136,520,000,000,000.00$17,295$681.69+$187025031600452665344.00M → CEOS
9$83,931,094,609,218,200,000,000,000,000$83,730,977,825,405,720,000,000,000,000.00$18,599$750.82+$8.39310946092182e+22M → CEOS
10$35,207,463,509,675,137,000,000,000,000,000$35,117,657,238,443,270,000,000,000,000,000.00$20,022$827.78+$3.5207463509675137e+25M → CEOS

CEOS vs JNJ: Complete Analysis 2026

CEOS — Stock

Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. Psykey, Inc. was founded in 2002 and is based in Toronto, Canada.

Full CEOS Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this CEOS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CEOS vs SCHDCEOS vs JEPICEOS vs OCEOS vs KOCEOS vs MAINCEOS vs ABBVCEOS vs MRKCEOS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.